Matches in Wikidata for { <http://www.wikidata.org/entity/Q91306877> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q91306877 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91306877 description "im November 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91306877 description "scientific article published on 13 November 2019" @default.
- Q91306877 description "wetenschappelijk artikel" @default.
- Q91306877 description "наукова стаття, опублікована 13 листопада 2019" @default.
- Q91306877 name "Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)" @default.
- Q91306877 name "Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)" @default.
- Q91306877 type Item @default.
- Q91306877 label "Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)" @default.
- Q91306877 label "Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)" @default.
- Q91306877 prefLabel "Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)" @default.
- Q91306877 prefLabel "Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)" @default.
- Q91306877 P1433 Q91306877-0BB0DF76-E051-4702-90C7-1804A7896A24 @default.
- Q91306877 P1476 Q91306877-B582705A-DB71-4042-AC83-97C68518B148 @default.
- Q91306877 P2093 Q91306877-102D57B5-2E88-4304-81F5-3C9AB35758FF @default.
- Q91306877 P2093 Q91306877-13F81655-CB8B-460B-9743-12C31AEBFC43 @default.
- Q91306877 P2093 Q91306877-20D04AC6-8C47-42C0-9CDD-13DBA72AC3CD @default.
- Q91306877 P2093 Q91306877-A8178EEB-3C1B-425E-9691-571D2035EBF8 @default.
- Q91306877 P2093 Q91306877-CAB08A00-233C-4FA2-970F-90E5D242E79D @default.
- Q91306877 P2093 Q91306877-E5285232-E2A5-44B8-BEDF-368CFBC0E113 @default.
- Q91306877 P304 Q91306877-426CD58B-3B9F-49C1-AE7C-BCC4BC9051D0 @default.
- Q91306877 P31 Q91306877-4200D9D4-07DC-4514-BDC9-206192A091FD @default.
- Q91306877 P356 Q91306877-DCC06951-1370-4806-B1F8-5658765058A4 @default.
- Q91306877 P433 Q91306877-8B61A7C9-E885-4539-96B1-4376433A4F0C @default.
- Q91306877 P478 Q91306877-D65ED24C-5866-43E3-BC08-0DD04136D19B @default.
- Q91306877 P577 Q91306877-07FD11F9-F42E-4257-A251-E9EF3743001A @default.
- Q91306877 P698 Q91306877-5ADF835A-8D5C-4E53-8C6F-50EA2813C8DD @default.
- Q91306877 P921 Q91306877-B3AA069B-2E20-415B-BE47-A610A03147BB @default.
- Q91306877 P356 J.EURURO.2019.10.002 @default.
- Q91306877 P698 31733990 @default.
- Q91306877 P1433 Q15763991 @default.
- Q91306877 P1476 "Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)" @default.
- Q91306877 P2093 "Adrian Wagg" @default.
- Q91306877 P2093 "Carol R Schermer" @default.
- Q91306877 P2093 "David Staskin" @default.
- Q91306877 P2093 "Eli Engel" @default.
- Q91306877 P2093 "Rita M Kristy" @default.
- Q91306877 P2093 "Sender Herschorn" @default.
- Q91306877 P304 "211-220" @default.
- Q91306877 P31 Q13442814 @default.
- Q91306877 P356 "10.1016/J.EURURO.2019.10.002" @default.
- Q91306877 P433 "2" @default.
- Q91306877 P478 "77" @default.
- Q91306877 P577 "2019-11-13T00:00:00Z" @default.
- Q91306877 P698 "31733990" @default.
- Q91306877 P921 Q269829 @default.